Research programme: fibroblast growth factor receptor-3 antibodies - Progenika Biopharma
Alternative Names: Research programme: bladder cancer - Progenika Biopharma; Research programme: FGFR3 antibodies - Progenika BiopharmaLatest Information Update: 16 Jul 2016
At a glance
- Originator Progenika Biopharma
- Class Monoclonal antibodies
- Mechanism of Action Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-cancer in Spain
- 22 Mar 2006 Preclinical trials in Bladder cancer in Spain (unspecified route)